reMYND to present on Biotechdag
reMYND will be presenting on the research towards the treatment of Alheimers and diabetes worldwide.
Read more
IWT supports reMYND in developing a cure for Type 1 Diabetes
reMYND announced that it has received a grant from IWT to assess the potential of its Diabetes program in curing Type 1 Diabetes Mellitus (T1DM).
Read more
Roche and reMYND's DDD enter into a strategic alliance to develop first-in-class disease-modifying treatments for Parkinson's and Alzheimer's disease
Roche (SIX: RO, ROG; OTCQX: RHHBY) and reMYND today announced that they have entered into an agreement.
Read more
Tulips for Parkinson’s
For 2014, reMYND has dedicated the proceeds of its new year cards to the Vlaamse Parkinson Liga as part of StuBru’s Music-for-Life action.
Read more
Ajit Shetty strengthens reMYND’s Board of Directors
reMYND NV today announced that its shareholders have elected Ajit Shetty to join the company’s 4-person Board as an Independent Director.
Read more
reMYND’s grant from the Michael J Fox Foundation in SciBX
The Science-Business eXchange devoted an article to the role the Michael J Fox Foundation has been playing in PD therapeutics.
Read more
IWT helps to accelerate reMYND’s Diabetes program with a grant of 1.48 million EUR for 2011-2012
reMYND NV today announced that it has received a grant of 1.48 million EUR to accelerate its Diabetes program.
Read more
reMYND’s CRO receives governmental grant for a continued innovation of its offering
The governmental Agency for Innovation by Science and Technology (IWT) has approved a grant to reMYND’s Contract Research Organization.
Read more
reMYND's CRO announces quarterly digital Newsletter
The prestigious Journal of Alzheimer's Disease publishes new data on reMYND's proprietary mouse models of Alzheimer's disease.
Read more
Review in Nature highlights reMYND's discovery platform
The growing interest in targeting protein misfolding to therapeutically treat both rare and common diseases was featured in Nature Reviews Drug Discovery.
Read more